☰

Donald J. Buchsbaum - Publications

Affiliations: 
Radiation Oncology University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Cell Biology, Biochemistry, Genetics
Website:
https://www.uab.edu/medicine/news/latest/item/1346-buchsbaum-named-to-national-academy-of-inventors
Tree Info Similar researchers PubMed Report error

274 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Bhalerao N, Chakraborty A, Marciel MP, Hwang J, Britain CM, Silva AD, Eltoum IE, Jones RB, Alexander KL, Smythies LE, Smith PD, Crossman DK, Crowley MR, Shin B, Harrington LE, ... ... Buchsbaum DJ, et al. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. Jci Insight. PMID 37643018 DOI: 10.1172/jci.insight.161563  0.308
2020 Ward AB, Keeton AB, Chen X, Mattox TE, Coley AB, Maxuitenko YY, Buchsbaum DJ, Randall TD, Zhou G, Piazza GA. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. Medcomm. 1: 121-128. PMID 33073260 DOI: 10.1002/Mco2.10  0.41
2020 Conway ME, McDaniel JM, Graham JM, Guillen KP, Oliver PG, Parker SL, Yue P, Turkson J, Buchsbaum DJ, Welm BE, Myers RM, Varley KE. STAT3 and GR cooperate to drive gene expression and growth of basal-like triple-negative breast cancer. Cancer Research. PMID 32816914 DOI: 10.1158/0008-5472.Can-20-1379  0.405
2020 Piazza GA, Ward A, Chen X, Maxuitenko Y, Coley A, Aboelella NS, Buchsbaum DJ, Boyd MR, Keeton AB, Zhou G. PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. Drug Discovery Today. PMID 32562844 DOI: 10.1016/J.Drudis.2020.06.008  0.463
2020 Agarwal S, Chakravarthi BVSK, Kim HG, Gupta N, Hale K, Balasubramanya SAH, Oliver PG, Thomas DG, Eltoum IA, Buchsbaum DJ, Manne U, Varambally S. PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. Translational Oncology. 13: 100776. PMID 32422575 DOI: 10.1016/J.Tranon.2020.100776  0.441
2020 Doo DW, Meza-Perez S, Londoño AI, Goldsberry WN, Katre AA, Boone JD, Moore DJ, Hudson CT, Betella I, McCaw TR, Gangrade A, Bao R, Luke JJ, Yang ES, Birrer MJ, ... ... Buchsbaum DJ, et al. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. Therapeutic Advances in Medical Oncology. 12: 1758835920913798. PMID 32313567 DOI: 10.1177/1758835920913798  0.453
2020 Piazza GA, Chen X, Ward A, Coley A, Zhou G, Buchsbaum DJ, Maxuitenko Y, Keeton AB. Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity Oncology Signaling. 3: 1-6. DOI: 10.1016/J.Onsig.2020.04.001  0.449
2019 McCaw TR, Li M, Starenki D, Liu M, Cooper SJ, Arend RC, Forero A, Buchsbaum DJ, Randall TD. Histone deacetylase inhibition promotes intratumoral CD8 T-cell responses, sensitizing murine breast tumors to anti-PD1. Cancer Immunology, Immunotherapy : Cii. PMID 31720815 DOI: 10.1007/S00262-019-02430-9  0.406
2019 Kasten BB, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted radioimmunotherapy of human cancer. Current Medicinal Chemistry. PMID 30836909 DOI: 10.2174/0929867326666190228120908  0.406
2018 Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Michael Straughn J, Norian LA, Arend RC. The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer. PMID 30423192 DOI: 10.1002/Cncr.31761  0.439
2018 McCaw TR, Li M, Starenki D, Cooper SJ, Liu M, Meza-Perez S, Arend RC, Buchsbaum DJ, Forero A, Randall TD. The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. Cancer Immunology, Immunotherapy : Cii. PMID 30334128 DOI: 10.1007/S00262-018-2262-5  0.385
2018 Gangrade A, Pathak V, Augelli-Szafran CE, Wei HX, Oliver P, Suto M, Buchsbaum DJ. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 19. PMID 29783777 DOI: 10.3390/Ijms19051524  0.385
2018 Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 9: 19459. PMID 29721216 DOI: 10.18632/oncotarget.25151  0.741
2018 Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ. Corrigendum to 'Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73]. Nuclear Medicine and Biology. PMID 29705525 DOI: 10.1016/J.Nucmedbio.2018.03.004  0.391
2018 Fancy RM, Kim H, Napier T, Buchsbaum DJ, Zinn KR, Song Y. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. Journal of Cellular Biochemistry. PMID 29663486 DOI: 10.1002/Jcb.26848  0.457
2018 Li Y, Oliver PG, Lu W, Pathak V, Sridharan S, Augelli-Szafran CE, Buchsbaum DJ, Suto MJ. Retraction notice to "SRI36160 is a specific inhibitor of Wnt/-catenin signaling in human pancreatic and colorectal cancer cells" [Canc. Lett. 389C (2017) 41-48]. Cancer Letters. 422: 131. PMID 29579438 DOI: 10.1016/J.Canlet.2018.03.017  0.409
2018 Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. International Journal of Molecular Sciences. 19. PMID 29561763 DOI: 10.3390/Ijms19040925  0.5
2018 Buchsbaum DJ. CD38 pretargeted RIT of B-cell tumors. Blood. 131: 589-590. PMID 29438968 DOI: 10.1182/Blood-2017-12-819011  0.33
2018 McCaw T, Turner T, Smith HM, Buchsbaum DJ, Randall T, Arend RC. Histone deacetylase inhibition alters tumor phenotype and stimulates a productive anti-tumor immune response in preclinical models of ovarian cancer. Journal of Clinical Oncology. 36: 5585-5585. DOI: 10.1200/Jco.2018.36.15_Suppl.5585  0.456
2018 Doo DW, Londono A, Meza-Perez S, Katre AA, Cooper SJ, Straughn JM, Buchsbaum DJ, Norian L, Randall T, Arend RC. Inhibition of the Wnt/β-catenin pathway to promote T-cell immunity and survival in a syngeneic mouse model of ovarian cancer. Journal of Clinical Oncology. 36: 5566-5566. DOI: 10.1200/Jco.2018.36.15_Suppl.5566  0.409
2018 Doo DW, Londono AI, Moore DJ, Meza-Perez S, Katre AA, McCaw TR, Smith HJ, Lin CY, Cooper SJ, Straughn JM, Buchsbaum DJ, Norian LA, Randall TD, Arend RC. Abstract 4710: The effect of Wnt inhibition combined with paclitaxel on tumor burden and CD8+ T cell infiltration in syngeneic murine models of ovarian cancer Cancer Research. 78: 4710-4710. DOI: 10.1158/1538-7445.Am2018-4710  0.472
2018 McCaw TR, Liu M, Li M, Starenki D, Cooper SJ, Arend RC, Forero A, Buchsbaum DJ, Randall TD. Abstract 4700: Manipulating the breast tumor microenvironment with histone deacetylase inhibitors for more robust and durable T cell responses Immunology. DOI: 10.1158/1538-7445.Am2018-4700  0.34
2018 Doo D, Londono A, Moore D, Katre A, Straughn J, Buchsbaum D, Norian L, Cooper S, Arend R. Inhibiting the wnt/β-catenin pathway modulates immune response in ovarian cancer Gynecologic Oncology. 149: 625. DOI: 10.1016/J.Ygyno.2018.03.022  0.362
2017 Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ. 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nuclear Medicine and Biology. 58: 67-73. PMID 29413459 DOI: 10.1016/J.Nucmedbio.2017.12.004  0.427
2017 Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, Buchsbaum DJ, Bellis SL. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. The Journal of Biological Chemistry. PMID 29191829 DOI: 10.1074/Jbc.M117.808584  0.41
2017 McCaw TR, Randall TD, Forero A, Buchsbaum DJ. Modulation of antitumor immunity with histone deacetylase inhibitors. Immunotherapy. 9: 1359-1372. PMID 29185390 DOI: 10.2217/Imt-2017-0134  0.314
2017 Naoum GE, Buchsbaum DJ, Tawadros F, Farooqi A, Arafat WO. Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncology Reviews. 11: 332. PMID 28584572 DOI: 10.4081/Oncol.2017.332  0.482
2017 Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM, Buchsbaum DJ, Randall TD, Arend RC. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget. PMID 28498806 DOI: 10.18632/Oncotarget.17395  0.423
2017 Smith HJ, Straughn JM, Buchsbaum DJ, Arend RC. Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. Gynecologic Oncology Reports. 20: 81-86. PMID 28378010 DOI: 10.1016/J.Gore.2017.03.007  0.428
2017 Naoum GE, Zhu ZB, Buchsbaum DJ, Curiel DT, Arafat WO. Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs. Clinical and Translational Medicine. 6: 11. PMID 28251571 DOI: 10.1186/S40169-017-0140-Y  0.552
2017 Pathak V, Augelli-Szafran CE, Wei HX, Li Y, Oliver PG, Lu W, Buchsbaum DJ, Suto MJ. Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry. PMID 28230988 DOI: 10.1021/Acs.Jmedchem.6B01417  0.407
2017 Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nuclear Medicine and Biology. 47: 23-30. PMID 28104527 DOI: 10.1016/J.Nucmedbio.2017.01.003  0.475
2017 Fancy RM, Kim H, Zhou T, Zinn KR, Buchsbaum DJ, Song Y. Calmodulin Binding to Death Receptor 5-mediated Death-inducing Signaling Complex in Breast Cancer Cells. Journal of Cellular Biochemistry. PMID 28092099 DOI: 10.1002/Jcb.25882  0.406
2017 McCaw TR, Li M, Meza-Perez S, Buchsbaum DJ, Starenki D, Cooper S, Forero A, Randall TD. Abstract 643: Induced MHCII expression on breast cancer cells broadens the responding T cell repertoire, delays tumor-specific T cell exhaustion, and impairs tumor growth Cancer Research. 77: 643-643. DOI: 10.1158/1538-7445.Am2017-643  0.446
2017 Li Y, Oliver PG, Lu W, Pathak V, Augelli-Szafran CE, Buchsbaum DJ, Suto MJ. Abstract 5173: Discovery of a series of benzimidazoles as potent Wnt/β-catenin signaling inhibitors in colorectal cancer cells Cancer Research. 77: 5173-5173. DOI: 10.1158/1538-7445.Am2017-5173  0.392
2017 Turner TB, Meza-Perez S, Peabody JE, Smith HJ, Norian LA, Buchsbaum DJ, Straughn JM, Randall T, Arend RC. Augmenting the MHC II antigen-presentation pathway with epigenetic therapy in epithelial ovarian cancer Gynecologic Oncology. 145: 90-91. DOI: 10.1016/J.Ygyno.2017.03.212  0.393
2017 Tawfik CM, Londono AI, Riyue B, Katre A, Cooper SJ, Straughn MJ, Buchsbaum DJ, Norian LA, Luke J, Arend RC. Overcoming Chemoresistance with the Inhibition of the Wnt Pathway in Ovarian Cancer Journal of the American College of Surgeons. 225: e131. DOI: 10.1016/J.Jamcollsurg.2017.07.879  0.419
2016 Li Y, Oliver PG, Lu W, Pathak V, Sridharan S, Augelli-Szafran CE, Buchsbaum DJ, Suto MJ. SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Letters. PMID 28043913 DOI: 10.1016/J.Canlet.2016.12.030  0.43
2016 McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, ... ... Buchsbaum DJ, et al. Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget. PMID 28030809 DOI: 10.18632/Oncotarget.14153  0.459
2016 Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. PMID 27888804 DOI: 10.18632/Oncotarget.13466  0.802
2016 Naoum GE, Tawadros F, Farooqi AA, Qureshi MZ, Tabassum S, Buchsbaum DJ, Arafat W. Role of nanotechnology and gene delivery systems in TRAIL-based therapies. Ecancermedicalscience. 10: 660. PMID 27594905 DOI: 10.3332/Ecancer.2016.660  0.455
2016 Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, Posey JA, Grizzle WE, Vickers SM, Buchsbaum DJ, Cooper SJ, et al. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Molecular Oncology. PMID 27282075 DOI: 10.1016/J.Molonc.2016.05.004  0.34
2016 Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, Conner MB, Arend RC, Yoon KJ, Klug C, Bullard DC, Kesterson RA, Oliver PG, O'Connor AK, Yoder BK, et al. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Research. PMID 27216178 DOI: 10.1158/0008-5472.Can-15-2834  0.508
2016 Turner TB, Buchsbaum DJ, Straughn JM, Randall TD, Arend RC. Ovarian cancer and the immune system - The role of targeted therapies. Gynecologic Oncology. PMID 27174875 DOI: 10.1016/J.Ygyno.2016.05.007  0.448
2016 Fancy RM, Wang L, Zeng Q, Wang H, Zhou T, Buchsbaum DJ, Song Y. Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-Negative and Estrogen Receptor Positive Breast Cancer Cells: An Integrated Experimental and Computational Study. The Journal of Biological Chemistry. PMID 27129269 DOI: 10.1074/Jbc.M116.727727  0.398
2016 Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE. Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunology Research. PMID 26980599 DOI: 10.1158/2326-6066.Cir-15-0243  0.437
2016 Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, Buchsbaum DJ, Samant RS, Shevde LA. Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget. PMID 26908451 DOI: 10.18632/Oncotarget.7494  0.418
2016 Kim H, Samuel SL, Lopez-Casas PP, Grizzle WE, Hidalgo M, Kovar J, Oelschlager DK, Zinn KR, Warram JM, Buchsbaum DJ. SPARC independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts. Molecular Cancer Therapeutics. PMID 26832793 DOI: 10.1158/1535-7163.Mct-15-0764  0.415
2016 Boone JD, Johnston BE, Cooper SJ, Straughn JM, Buchsbaum DJ, Arend RC. Transcriptional expression patterns of patient-derived tumorspheres predict outcomes in high-grade serous ovarian carcinoma. Journal of Clinical Oncology. 34: e23125-e23125. DOI: 10.1200/Jco.2016.34.15_Suppl.E23125  0.324
2016 Turner TB, Arend RC, Li M, Randall TD, Forero-Torres A, LoBuglio AF, Straughn JM, Buchsbaum DJ. Abstract 4030: Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line Cancer Research. 76: 4030-4030. DOI: 10.1158/1538-7445.Am2016-4030  0.46
2016 Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, Conner MG, Arend RC, Yoon KJ, Klug CA, Bullard DC, Kesterson RA, Oliver PG, O’Connor AK, Yoder BK, et al. Abstract 3327: The tumor associated sialyltransferase ST6Gal-I promotes a cancer stem cell phenotype and upregulates stem-related transcription factors Cancer Research. 76: 3327-3327. DOI: 10.1158/1538-7445.Am2016-3327  0.49
2016 Li M, McCaw TR, Meza-Perez S, Randall TD, Weinmann A, Buchsbaum DJ, Forero A, LoBuglio AF. Abstract 1461: MHCII-expressing breast cancer cells can induce anti-tumor immune response Cancer Research. 76: 1461-1461. DOI: 10.1158/1538-7445.Am2016-1461  0.49
2015 Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G, Gangrade A, Straughn JM, Buchsbaum DJ. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 26658453 DOI: 10.1038/Labinvest.2015.150  0.485
2015 Ludwig MR, Kojima K, Bowersock GJ, Chen D, Jhala NC, Buchsbaum DJ, Grizzle WE, Klug CA, Mobley JA. Surveying the serologic proteome in a tissue specific kras(G12D) knockin mouse model of pancreatic cancer. Proteomics. PMID 26572242 DOI: 10.1002/Pmic.201500133  0.392
2015 Kim H, Buchsbaum DJ, Zinn KR. A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 26552657 DOI: 10.1007/S11307-015-0913-X  0.336
2015 Arafat W, Zhou T, Naoum GE, Buchsbaum DJ. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. Journal of the Egyptian National Cancer Institute. 27: 205-15. PMID 26385392 DOI: 10.1016/J.Jnci.2015.08.003  0.453
2015 Walters Haygood CL, Arend RC, Gangrade A, Chettiar S, Regan N, Hassmann CJ, Li PK, Hidalgo B, Straughn JM, Buchsbaum DJ. Niclosamide Analogs for Treatment of Ovarian Cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 25: 1377-85. PMID 26186072 DOI: 10.1097/Igc.0000000000000506  0.486
2015 Boone JD, Dobbin ZC, Straughn JM, Buchsbaum DJ. Ovarian and cervical cancer patient derived xenografts: The past, present, and future. Gynecologic Oncology. 138: 486-91. PMID 26026736 DOI: 10.1016/J.Ygyno.2015.05.022  0.461
2015 Kim H, Samuel S, Totenhagen JW, Warren M, Sellers JC, Buchsbaum DJ. Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model. Journal of Visualized Experiments : Jove. PMID 25938718 DOI: 10.3791/52641  0.367
2015 Che P, Yang Y, Han X, Hu M, Sellers JC, Londono-Joshi AI, Cai GQ, Buchsbaum DJ, Christein JD, Tang Q, Chen D, Li Q, Grizzle WE, Lu YY, Ding Q. S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Scientific Reports. 5: 8453. PMID 25677816 DOI: 10.1038/Srep08453  0.803
2015 Forero-Torres A, Varley KE, Li Y, Chen D, Grizzle WE, Downs-Kelly E, Burwell TC, Buchsbaum DJ, Myers RM, LoBuglio AF. MHC II antigen presentation pathway expression in triple-negative breast cancer. Journal of Clinical Oncology. 33: 1066-1066. DOI: 10.1200/Jco.2015.33.15_Suppl.1066  0.414
2015 Arend RC, Gangrade A, Haygood CLW, Kurpad C, Metge BJ, Samant RS, Li P, Li Y, Bhasin D, Landen C, Alvarez R, Straughn JM, Buchsbaum DJ. Abstract POSTER-THER-1402: Overcoming platinum resistance in ovarian cancer with niclosamide Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1402  0.499
2015 Buchsbaum DJ, Zhou T. Abstract A100: Role of HER3 ligand-independent activation in EGFR resistance in pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A100  0.447
2015 Fancy RM, Buchsbaum DJ, Zhou T, Song Y. Abstract 2931: Calmodulin-DR5 binding in breast cancer: Independent of TRA-8 sensitivity Cancer Research. 75: 2931-2931. DOI: 10.1158/1538-7445.Am2015-2931  0.406
2014 Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World Journal of Stem Cells. 6: 441-7. PMID 25258665 DOI: 10.4252/Wjsc.V6.I4.441  0.453
2014 Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ, Zinn KR. Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biology & Therapy. 15: 1053-60. PMID 25084100 DOI: 10.4161/Cbt.29183  0.482
2014 Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A, Buchsbaum DJ, LoBuglio AF, Myers RM. Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Research and Treatment. 146: 287-97. PMID 24929677 DOI: 10.1007/S10549-014-3019-2  0.382
2014 Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Curiel DT. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Therapy. 21: 264-74. PMID 24903014 DOI: 10.1038/Cgt.2014.26  0.551
2014 Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecologic Oncology. 134: 112-20. PMID 24736023 DOI: 10.1016/J.Ygyno.2014.04.005  0.783
2014 Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Letters. 349: 8-14. PMID 24732808 DOI: 10.1016/J.Canlet.2014.04.003  0.463
2014 Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ. Effect of niclosamide on basal-like breast cancers. Molecular Cancer Therapeutics. 13: 800-11. PMID 24552774 DOI: 10.1158/1535-7163.Mct-13-0555  0.801
2014 Buchsbaum DJ, Croce CM. Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? Jama. 311: 363-5. PMID 24449314 DOI: 10.1001/Jama.2013.284665  0.417
2014 Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM, Landen CN, Ferrone S, Buchsbaum DJ. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic Oncology. 132: 203-10. PMID 24216048 DOI: 10.1016/J.Ygyno.2013.10.038  0.805
2014 Kim H, Rigell CJ, Zhai G, Lee SK, Samuel SL, Martin A, Umphrey HR, Stockard CR, Beasley TM, Buchsbaum DJ, Li LS, Boothman DA, Zinn KR. Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 85-94. PMID 23836505 DOI: 10.1007/S11307-013-0665-4  0.437
2014 Devine DJ, Rostas JW, Metge BJ, Das S, Mulekar MS, Tucker JA, Grizzle WE, Buchsbaum DJ, Shevde LA, Samant RS. Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling. Oncogene. 33: 2620-8. PMID 23770854 DOI: 10.1038/Onc.2013.215  0.378
2014 Haygood CLW, Arend RC, Li P, Li Y, Kurpad C, Gangrade A, Straughn JM, Buchsbaum D. Abstract 4677: Niclosamide analogs for treatment of ovarian cancer Cancer Research. 74: 4677-4677. DOI: 10.1158/1538-7445.Am2014-4677  0.426
2014 Arend RC, Haygood CLW, Kurpad C, Gangrade A, Li P, Li Y, Bhasin D, Straughn JM, Buchsbaum DJ. Abstract 2517: STAT3 inhibition by LLL12 in combination with niclosamide and chemotherapy in ovarian cancer Cancer Research. 74: 2517-2517. DOI: 10.1158/1538-7445.Am2014-2517  0.472
2014 Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Curiel DT. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus Cancer Gene Therapy. 21: 264-274. DOI: 10.1038/cgt.2014.26  0.486
2014 Haygood CLW, Arend RC, Londono-Joshi A, Kurpad C, Katre AA, Conner MG, Landen CN, Straughn JM, Buchsbaum DJ. Ovarian cancer ascites stem cell population compared to primary tumor Gynecologic Oncology. 133: 122. DOI: 10.1016/J.Ygyno.2014.03.320  0.788
2014 Arend RC, Haygood CLW, Li Y, Kurpad C, Gangrade A, Straughn M, Buchsbaum DJ. Wnt pathway inhibition by niclosamide: a therapeutic target for ovarian cancer Gynecologic Oncology. 133: 121. DOI: 10.1016/J.Ygyno.2014.03.317  0.42
2013 Arend RC, Londoño-Joshi AI, Straughn JM, Buchsbaum DJ. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecologic Oncology. 131: 772-9. PMID 24125749 DOI: 10.1016/J.Ygyno.2013.09.034  0.777
2013 Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, ... Buchsbaum DJ, et al. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Molecular Cancer Therapeutics. 12: 2110-2120. PMID 23883585 DOI: 10.1158/1535-7163.Mct-12-0962  0.428
2013 Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE, Straughn JM, Buchsbaum DJ, Grizzle WE, McNally LR. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. Annals of Surgical Oncology. 20: 3059-65. PMID 23525731 DOI: 10.1245/S10434-013-2878-9  0.763
2013 Lin C, Lu W, Zhang W, Londoño-Joshi AI, Buchsbaum DJ, Bu G, Li Y. The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells. Plos One. 8: e58102. PMID 23469146 DOI: 10.1371/Journal.Pone.0058102  0.756
2013 Swindall AF, Londoño-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Research. 73: 2368-78. PMID 23358684 DOI: 10.1158/0008-5472.Can-12-3424  0.782
2013 Londono-Joshi AI, Arend RC, Aristizabal L, Li Y, Lu W, Samant RS, Metge BJ, Forero A, Zhou T, LoBuglio AF, Buchsbaum DJ. Abstract 865: Inhibition of Wnt co-receptor LRP6 sensitizes basal-like breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody. Cancer Research. 73: 865-865. DOI: 10.1158/1538-7445.Am2013-865  0.808
2013 Cai G, Kerr EH, Hu M, Yang Y, Buchsbaum DJ, Grizzle WE, Ding Q. Abstract 4013: S100A4 promotes cell migration and growth through focal adhesion kinase and Src mediated dual signaling pathways in pancreatic cancer cells. Cancer Research. 73: 4013-4013. DOI: 10.1158/1538-7445.Am2013-4013  0.438
2013 Arend RC, Londoño-Joshi AI, Li Y, Lu W, Samant RS, Metge BJ, Straughn JM, Buchsbaum DJ. Abstract 2179: Wnt pathway inhibition by niclosamide: a therapeutic target for ovarian cancer. Cancer Research. 73: 2179-2179. DOI: 10.1158/1538-7445.Am2013-2179  0.775
2013 Arafat W, Anderson J, Welaya K, Willey C, Gillespie Y, Buchsbaum D. Triple Therapy Using Radiation Therapy (RT), Temozolomide (TMZ), and TRAIL Agonist (TRA-8) Enhances Cell Killing in Primary Glioma Cancer Stem Cells Associated With Changes in Distinct Tyrosine Kinase Signaling Cascades Identified Through Kinomic Analysis International Journal of Radiation Oncology*Biology*Physics. 87: S140. DOI: 10.1016/J.Ijrobp.2013.06.361  0.402
2012 Kaliberov SA, Buchsbaum DJ. Chapter seven--Cancer treatment with gene therapy and radiation therapy. Advances in Cancer Research. 115: 221-63. PMID 23021246 DOI: 10.1016/B978-0-12-398342-8.00007-0  0.378
2012 Fauci JM, Straughn JM, Ferrone S, Buchsbaum DJ. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecologic Oncology. 127: 420-5. PMID 22910694 DOI: 10.1016/J.Ygyno.2012.08.017  0.366
2012 Oh S, Todhunter DA, Panoskaltsis-Mortari A, Buchsbaum DJ, Toma S, Vallera DA. A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model. Pancreas. 41: 789-96. PMID 22258068 DOI: 10.1097/Mpa.0B013E31823B5F2E  0.403
2012 Buchsbaum DJ. Progress in cancer therapy. Cancer Biotherapy & Radiopharmaceuticals. 27: 1. PMID 22233333 DOI: 10.1089/Cbr.2012.1201  0.394
2012 Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM, Buchsbaum DJ. The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecologic Oncology. 125: 226-30. PMID 22155260 DOI: 10.1016/J.Ygyno.2011.12.425  0.785
2012 Whitworth JM, Straughn JM, Atigadda VR, Muccio DD, Buchsbaum DJ. The use of retinoids in ovarian cancer: a review of the literature. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: 191-8. PMID 22146768 DOI: 10.1097/Igc.0B013E318236A2Ec  0.379
2012 Londoño-Joshi AI, Oliver PG, Li Y, Lee CH, Forero-Torres A, LoBuglio AF, Buchsbaum DJ. Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Research and Treatment. 133: 437-45. PMID 21915634 DOI: 10.1007/S10549-011-1763-0  0.799
2012 Oliver PG, LoBuglio AF, Zhou T, Forero A, Kim H, Zinn KR, Zhai G, Li Y, Lee CH, Buchsbaum DJ. Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast Cancer Research and Treatment. 133: 417-26. PMID 21901385 DOI: 10.1007/S10549-011-1755-0  0.482
2012 Buchsbaum DJ, Chen X, Shen E, Zhou T. Abstract A25: Novel anti-HER3 strategy for pancreatic cancer therapy. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A25  0.452
2011 Ayyasamy V, Owens KM, Desouki MM, Liang P, Bakin A, Thangaraj K, Buchsbaum DJ, LoBuglio AF, Singh KK. Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. Plos One. 6: e24792. PMID 21935467 DOI: 10.1371/Journal.Pone.0024792  0.43
2011 Amm HM, Buchsbaum DJ. Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer. Expert Review of Anticancer Therapy. 11: 1193-6. PMID 21916572 DOI: 10.1586/Era.11.108  0.788
2011 Huang ZQ, Saluja AK, Dudeja V, Vickers SM, Buchsbaum DJ. Molecular targeted approaches for treatment of pancreatic cancer Current Pharmaceutical Design. 17: 2221-2238. PMID 21777178 DOI: 10.2174/138161211796957427  0.487
2011 Bonner JA, Willey CD, Yang ES, Dobelbower MC, Sanford LL, Bright SJ, Buchsbaum DJ, Raisch KP. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 101: 183-9. PMID 21722984 DOI: 10.1016/J.Radonc.2011.05.083  0.428
2011 Garg P, Yang S, Liu A, Pallero MA, Buchsbaum DJ, Mosher DF, Murphy-Ullrich JE, Goldblum SE. Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. American Journal of Physiology. Lung Cellular and Molecular Physiology. 301: L79-90. PMID 21531776 DOI: 10.1152/Ajplung.00287.2010  0.311
2011 Kim H, Folks KD, Guo L, Sellers JC, Fineberg NS, Stockard CR, Grizzle WE, Buchsbaum DJ, Morgan DE, George JF, Zinn KR. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Molecular Imaging. 10: 153-67. PMID 21496446 DOI: 10.2310/7290.2010.00040  0.392
2011 Amm HM, Zhou T, Steg AD, Kuo H, Li Y, Buchsbaum DJ. Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Molecular Cancer Research : McR. 9: 403-17. PMID 21357440 DOI: 10.1158/1541-7786.Mcr-10-0133  0.792
2011 Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biology & Therapy. 11: 431-49. PMID 21263219 DOI: 10.4161/Cbt.11.5.14671  0.799
2011 Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM, Buchsbaum DJ. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecologic Oncology. 121: 193-9. PMID 21211830 DOI: 10.1016/J.Ygyno.2010.11.046  0.805
2011 Arnoletti JP, Frolov A, Eloubeidi M, Keene K, Posey J, Wood T, Greeno E, Jhala N, Varadarajulu S, Russo S, Christein J, Oster R, Buchsbaum DJ, Vickers SM. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 67: 891-7. PMID 20589377 DOI: 10.1007/S00280-010-1383-0  0.386
2011 Kim H, Folks KD, Guo L, Stockard CR, Fineberg NS, Grizzle WE, George JF, Buchsbaum DJ, Morgan DE, Zinn KR. DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 13: 94-103. PMID 20383593 DOI: 10.1007/S11307-010-0320-2  0.355
2011 Whitworth JM, Oliver PJ, Muccio DD, Straughn JM, Buchsbaum DJ. Abstract 181: The combination of a novel retinoid compound with standard chemotherapy increases cytotoxicity in an ovarian cancer cell line Cancer Research. 71: 181-181. DOI: 10.1158/1538-7445.Am2011-181  0.448
2011 Kerr EH, Frederick PJ, Oelschlager DK, Amm H, Sellers J, Manna DD, Buchsbaum DJ, Grizzle WE, McNally LR. Abstract 1714: Chemoresistance in patients with papillary serous carcinoma of the ovary Cancer Research. 71: 1714-1714. DOI: 10.1158/1538-7445.Am2011-1714  0.782
2011 Meredith RF, Raisch KP, Buchsbaum DJ, Spencer SA. Pazopanib Combined With Radiation: An In Vivo Model International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.1238  0.395
2011 Ayyasamy V, Owens KM, Desouki MM, Liang P, Bakin A, Thangaraj K, Buchsbaum DJ, LoBuglio AF, Singh KK. Genetic insights into Warburg Effect reveal tumor promoting function of UCP2 Free Radical Biology and Medicine. 51: S7. DOI: 10.1016/J.Freeradbiomed.2011.10.014  0.309
2010 McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC, Huang ZQ, Grizzle WE, Stockard CR, Nash KT, Buchsbaum DJ. KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clinical & Experimental Metastasis. 27: 591-600. PMID 20844932 DOI: 10.1007/S10585-010-9349-5  0.42
2010 Bevis KS, Buchsbaum DJ, Straughn JM. Overcoming TRAIL resistance in ovarian carcinoma. Gynecologic Oncology. 119: 157-63. PMID 20638107 DOI: 10.1016/J.Ygyno.2010.05.034  0.494
2010 Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA. A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas. 39: 913-22. PMID 20182395 DOI: 10.1097/Mpa.0B013E3181Cbd908  0.428
2010 Joshi AIL, Oliver PG, Forero A, LoBuglio AF, Buchsbaum DJ. Abstract LB-260: Sensitivity of breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-260  0.463
2010 Kim H, Folks K, Guo L, Sellers J, Fineberg N, Stockard C, Grizzle W, Buchsbaum D, Morgan D, George J, Zinn K. Abstract 641: Early therapy assessment of cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging Cancer Research. 70: 641-641. DOI: 10.1158/1538-7445.Am10-641  0.398
2010 McNally LR, Frederick PJ, Bevis KS, Sellers JC, Manna DLD, Straughn JM, Stockard CR, Grizzle WE, Buchsbaum DJ. Abstract 2688: The expression of lung resistance protein (LRP) in patient ascites predicts platinum resistance in advanced epithelial ovarian carcinoma Cancer Research. 70: 2688-2688. DOI: 10.1158/1538-7445.Am10-2688  0.432
2009 Huang ZQ, Buchsbaum DJ. Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy. 1: 223-9. PMID 20046965 DOI: 10.2217/1750743X.1.2.223  0.486
2009 Kaliberova LN, Kusmartsev SA, Krendelchtchikova V, Stockard CR, Grizzle WE, Buchsbaum DJ, Kaliberov SA. Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression. Molecular Cancer Therapeutics. 8: 3130-9. PMID 19887544 DOI: 10.1158/1535-7163.Mct-09-0270  0.508
2009 Frederick PJ, Kendrick JE, Straughn JM, Della Manna DL, Oliver PG, Lin HY, Grizzle WE, Stockard CR, Alvarez RD, Zhou T, LoBuglio AF, Buchsbaum DJ. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 19: 814-9. PMID 19574765 DOI: 10.1111/Igc.0B013E3181A2A003  0.447
2009 Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, McNally LR, Buchsbaum DJ, Rosenthal EL. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4058-65. PMID 19509148 DOI: 10.1158/1078-0432.Ccr-09-0212  0.426
2009 Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, Kusmartsev S. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancer Journal of Immunology. 182: 7548-7557. PMID 19494278 DOI: 10.4049/Jimmunol.0802358  0.456
2009 Li J, Wang Y, Yang C, Wang P, Oelschlager DK, Zheng Y, Tian DA, Grizzle WE, Buchsbaum DJ, Wan M. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Molecular Pharmacology. 76: 81-90. PMID 19395473 DOI: 10.1124/Mol.109.054551  0.483
2009 Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, Gillespie GY, Grizzle WE, Buchsbaum DJ, Kaliberov SA. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Therapy. 16: 794-805. PMID 19363468 DOI: 10.1038/Cgt.2009.23  0.53
2009 Frederick PJ, Straughn JM, Alvarez RD, Buchsbaum DJ. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecologic Oncology. 113: 384-90. PMID 19232697 DOI: 10.1016/J.Ygyno.2009.01.008  0.433
2009 Skipper JB, McNally LR, Rosenthal EL, Wang W, Buchsbaum DJ. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. Orl; Journal For Oto-Rhino-Laryngology and Its Related Specialties. 71: 1-5. PMID 18931526 DOI: 10.1159/000163217  0.392
2009 McNally LR, Rosenthal EL, Zhang W, Buchsbaum DJ. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation. Cancer Gene Therapy. 16: 246-55. PMID 18846112 DOI: 10.1038/Cgt.2008.76  0.39
2008 Frederick PJ, Kendrick JE, Straughn JM, Oliver PG, Lin H, Manna DL, LoBuglio AF, Buchsbaum DJ. Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14695. PMID 27949554 DOI: 10.1200/Jco.2008.26.15_Suppl.14695  0.441
2008 Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, Forero A, Zinn KR. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Research. 68: 8369-76. PMID 18922909 DOI: 10.1158/0008-5472.Can-08-1771  0.379
2008 Wang D, Stockard CR, Harkins L, Lott P, Salih C, Yuan K, Buchsbaum D, Hashim A, Zayzafoon M, Hardy RW, Hameed O, Grizzle W, Siegal GP. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission. 83: 179-89. PMID 18846440 DOI: 10.1080/10520290802451085  0.372
2008 Kaliberova LN, Della Manna DL, Krendelchtchikova V, Black ME, Buchsbaum DJ, Kaliberov SA. Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Molecular Cancer Therapeutics. 7: 2845-54. PMID 18790765 DOI: 10.1158/1535-7163.Mct-08-0347  0.475
2008 Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. American Journal of Surgery. 196: 430-41. PMID 18718222 DOI: 10.1016/J.Amjsurg.2008.04.009  0.442
2008 Tseng CW, Monie A, Trimble C, Alvarez RD, Huh WK, Buchsbaum DJ, Straughn JM, Wang MC, Yagita H, Hung CF, Wu TC. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine. 26: 4314-9. PMID 18598733 DOI: 10.1016/J.Vaccine.2008.06.049  0.413
2008 Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. International Journal of Radiation Oncology, Biology, Physics. 71: 507-16. PMID 18474311 DOI: 10.1016/J.Ijrobp.2008.02.005  0.813
2008 Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2180-9. PMID 18381960 DOI: 10.1158/1078-0432.Ccr-07-1392  0.519
2008 Vallera DA, Stish BJ, Shu Y, Chen H, Saluja A, Buchsbaum DJ, Vickers SM. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model Gut. 57: 634-641. PMID 18222985 DOI: 10.1136/Gut.2007.137802  0.343
2008 Kendrick JE, Straughn JM, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD, Buchsbaum DJ. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecologic Oncology. 108: 591-7. PMID 18177927 DOI: 10.1016/J.Ygyno.2007.11.039  0.458
2008 Oh S, Stish B, Saluja A, Vickers SM, Buchsbaum DJ, Vallera DA. Potent And Prolonged Therapeutic Activity Of Recombinant Bispecific Ligand-Directed Toxin (Blt), Dtegf13 Against Orthotopic Pancreatic Cancer In Nude Mice Pancreas. 37: 488. DOI: 10.1097/01.Mpa.0000335354.78771.Bb  0.379
2008 Safavy S, Nichole D, Newman JR, Wenyue Z, Weeks DM, Helman EE, Buchsbaum DJ, Rosenthal EL. R422 – EMMPRIN as a Novel Target in Head and Neck Cancer Otolaryngology-Head and Neck Surgery. 139: 185. DOI: 10.1016/J.Otohns.2008.05.576  0.394
2008 Long JW, Buchsbaum DJ, Sellers J, Huang Z, Vickers SM, Arnoletti P. QS303. Erlotinib Reduces Flip Mediated Resistance to TRA-8 Agonistic TRAIL-R2 Antibody in Pancreatic Cancer Cells Journal of Surgical Research. 144: 387-388. DOI: 10.1016/J.Jss.2007.12.555  0.417
2008 Smith SM, Arnoletti JP, Buchsbaum DJ, Vickers SM. 54. Combination Therapy Using DR4 and DR5 TRAIL Antibodies, Gemcitabine, and Radiation Inhibits Pancreatic Cancer Growth in an Animal Model Journal of Surgical Research. 144: 199-200. DOI: 10.1016/J.Jss.2007.12.062  0.411
2008 Fiveash J, Buchsbaum D, Gillespie GY. In Reply to Dr. Speer International Journal of Radiation Oncology Biology Physics. 72: 1274. DOI: 10.1016/J.Ijrobp.2008.07.045  0.44
2007 Derosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, Sellers J, Stockard CR, Zhou T, Oliver PG, Arnoletti P, Lobuglio AF, Buchsbaum DJ. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Molecular Cancer Therapeutics. 6: 3198-207. PMID 18089714 DOI: 10.1158/1535-7163.Mct-07-0299  0.523
2007 Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. The Journal of Surgical Research. 143: 20-6. PMID 17950068 DOI: 10.1016/J.Jss.2007.01.051  0.373
2007 Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5643s-5645s. PMID 17875801 DOI: 10.1158/1078-0432.Ccr-07-0985  0.441
2007 DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5535s-5543s. PMID 17875786 DOI: 10.1158/1078-0432.Ccr-07-1075  0.476
2007 Buchsbaum DJ, Forero-Torres A, LoBuglio AF. TRAIL-receptor antibodies as a potential cancer treatment. Future Oncology (London, England). 3: 405-9. PMID 17661715 DOI: 10.2217/14796694.3.4.405  0.487
2007 Kendrick JE, Estes JM, Straughn JM, Alvarez RD, Buchsbaum DJ. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecologic Oncology. 106: 614-21. PMID 17602728 DOI: 10.1016/J.Ygyno.2007.05.035  0.456
2007 Kaliberov SA, Market JM, Gillespie GY, Krendelchtchikova V, Della Manna D, Sellers JC, Kaliberova LN, Black ME, Buchsbaum DJ. Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. Gene Therapy. 14: 1111-9. PMID 17495948 DOI: 10.1038/Sj.Gt.3302965  0.592
2007 Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, Arnoletti JP. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biology & Therapy. 6: 548-54. PMID 17457047 DOI: 10.4161/Cbt.6.4.3849  0.466
2007 Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Annals of Surgical Oncology. 14: 2150-8. PMID 17453292 DOI: 10.1245/S10434-007-9409-5  0.336
2007 Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ, Arnoletti JP. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 141: 464-9. PMID 17383523 DOI: 10.1016/J.Surg.2006.09.009  0.385
2007 Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Molecular Cancer Therapeutics. 6: 866-75. PMID 17363481 DOI: 10.1158/1535-7163.Mct-06-0230  0.372
2007 Estes JM, Oliver PG, Straughn JM, Zhou T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBuglio AF, Buchsbaum DJ. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecologic Oncology. 105: 291-8. PMID 17303227 DOI: 10.1016/J.Ygyno.2006.12.033  0.427
2007 Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. Single-photon emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts Cancer Biology and Therapy. 6: 1396-1402. DOI: 10.4161/Cbt.6.9.4540  0.392
2007 Tzeng CD, Frolov A, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP. 96: Analysis of aberrant epidermal growth factor receptor (EGFR) pathway signaling in pancreatic cancer patients: Implications for anti-EGFR therapy Journal of Surgical Research. 137: 1-1. DOI: 10.1016/J.Jss.2006.12.107  0.357
2007 Derosier LC, Buchsbaum DJ, Sellers J, Huang ZQ, Oliver PG, Wang W, Kurt Z, Vickers SM. 45: Treatment with a monoclonal death receptor-5 antibody and Irinotecan increases survival in a radiologically verified model of pancreatic cancer Journal of Surgical Research. 137: 1-9. DOI: 10.1016/J.Jss.2006.12.054  0.408
2007 Long JW, Derosier LC, Vickers SM, Sellers J, Wang W, Arnoletti JP, Buchsbaum DJ. 40: TRA-8 (TRAIL-R2 antibody) based combination chemotherapy produces a survival benefit in a pancreatic cancer orthotopic model Journal of Surgical Research. 137. DOI: 10.1016/J.Jss.2006.12.049  0.385
2006 Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. Oncolytic HSV-1 for the treatment of brain tumours. Herpes : the Journal of the Ihmf. 13: 66-71. PMID 17147910  0.43
2006 DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 10: 1291-300; discussion. PMID 17114015 DOI: 10.1016/J.Gassur.2006.08.007  0.509
2006 Li Y, Wang H, Wang Z, Makhija S, Buchsbaum D, LoBuglio A, Kimberly R, Zhou T. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function Cancer Research. 66: 8520-8528. PMID 16951164 DOI: 10.1158/0008-5472.Can-05-4364  0.469
2006 Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncology (London, England). 2: 493-508. PMID 16922616 DOI: 10.2217/14796694.2.4.493  0.494
2006 Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. The Journal of Molecular Diagnostics : Jmd. 8: 76-83. PMID 16436637 DOI: 10.2353/Jmoldx.2006.040402  0.345
2006 Kaliberov SA, Buchsbaum DJ. Gene delivery and gene therapy of prostate cancer. Expert Opinion On Drug Delivery. 3: 37-51. PMID 16370939 DOI: 10.1517/17425247.3.1.37  0.345
2006 Straughn JM, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecologic Oncology. 101: 46-54. PMID 16271751 DOI: 10.1016/J.Ygyno.2005.09.053  0.463
2006 Kaliberov SA, Chiz S, Kaliberova LN, Krendelchtchikova V, Della Manna D, Zhou T, Buchsbaum DJ. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity Cancer Gene Therapy. 13: 203-214. PMID 16082379 DOI: 10.1038/Sj.Cgt.7700874  0.444
2006 Roberson P, Buchsbaum D. SU‐FF‐T‐264: Impact of Heterogeneous Activity Distributions On the Tumor Absorbed Dose Distribution for An In‐Vivo Colorectal Cancer Model Medical Physics. 33: 2108-2108. DOI: 10.1118/1.2241184  0.346
2006 Kaliberov SA, Krendelchtchikova V, Manna DD, Sellers JC, Kaliberova LN, Black ME, Buchsbaum DJ. 947. Gene Directed Enzyme/Prodrug Therapy of Human Glioma Xenografts Using Mutant Escherichia coli Cytosine Deaminase Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.1038  0.411
2006 DeRosier LC, Buchsbaum DJ, Sellers JC, Huang ZQ, Oliver PG, Vickers SM. Combination of irinotecan and anti-death receptor 5 antibody inhibits pancreatic cancer in an orthotopic tumor model Journal of Surgical Research. 130: 220. DOI: 10.1016/J.Jss.2005.11.164  0.471
2006 Tzeng CD, Frolov A, Frolova N, Jhala NC, Frost AR, Howard JH, Schuller KW, Buchsbaum DJ, Vickers SM, Heslin MJ, Arnoletti JP. Mechanisms of aberrant epidermal growth factor receptor signaling in the absence of EGFR gene activating mutations in pancreatic cancer patients Journal of the American College of Surgeons. 203: S85. DOI: 10.1016/J.Jamcollsurg.2006.05.222  0.318
2005 Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8773-81. PMID 16361565 DOI: 10.1158/1078-0432.Ccr-05-0627  0.415
2005 Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8180-5. PMID 16299250 DOI: 10.1158/1078-0432.Ccr-05-0607  0.375
2005 Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biotherapy & Radiopharmaceuticals. 20: 502-13. PMID 16248766 DOI: 10.1089/Cbr.2005.20.502  0.395
2005 Kamradt MC, Lu M, Werner ME, Kwan T, Chen F, Strohecker A, Oshita S, Wilkinson JC, Yu C, Oliver PG, Duckett CS, Buchsbaum DJ, LoBuglio AF, Jordan VC, Cryns VL. The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3 Journal of Biological Chemistry. 280: 11059-11066. PMID 15653686 DOI: 10.1074/Jbc.M413382200  0.405
2005 Buchsbaum DJ, Chaudhuri TR, Zinn KR. Radiotargeted gene therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 179S-86S. PMID 15653667  0.311
2005 Kaliberov SA, Kaliberova LN, Buchsbaum DJ. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas Gene Therapy. 12: 407-417. PMID 15616600 DOI: 10.1038/Sj.Gt.3302432  0.401
2005 Fiveash JB, Buchsbaum DJ, Gillespie GY. TRAIL death receptor therapy for malignant glioma Journal of Clinical Oncology. 23: 3187-3187. DOI: 10.1200/Jco.2005.23.16_Suppl.3187  0.578
2005 Arafat WO, Buchsbaum DJ. TRAIL-mediated induction of apoptosis as a targeted therapy for prostate cancer Journal of Clinical Oncology. 23: 3186-3186. DOI: 10.1200/Jco.2005.23.16_Suppl.3186  0.425
2005 Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ. Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513)) Cancer Biotherapy and Radiopharmaceuticals. 20. DOI: 10.1089/Cbr.2005.20.671  0.353
2005 Kaliberov SA, Kaliberova LN, Petersen AS, Krendelchtchikova V, Krasnykh V, Buchsbaum DJ. 529. Oncolytic Virotherapy Employing flt-1 Driven mda-7/IL-24 Gene Delivery|[ast]| Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.069  0.494
2005 DeRosier LC, Buchsbaum D, Sellers J, Huang Z, Oliver P, Vickers S. Treatment of pancreatic cancer with anti-death receptor antibody in combination with Gemcitabine Journal of the American College of Surgeons. 201. DOI: 10.1016/J.Jamcollsurg.2005.06.018  0.417
2004 Arafat WO, Rein D, Buchsbaum D, Curiel D, Zhu Z. Survivin as a novel radiation/CIS platinum/tumor specific promoter for conditional oncolytic viral therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1535. PMID 28015408 DOI: 10.1200/Jco.2004.22.14_Suppl.1535  0.554
2004 Chaudhuri TR, Cao Z, Ponnazhagan S, Stargel A, Simhadri PL, Zhou T, Lobuglio AF, Buchsbaum DJ, Zinn KR. Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 742. PMID 28013631 DOI: 10.1200/Jco.2004.22.14_Suppl.742  0.456
2004 Arnoletti JP, Buchsbaum DJ, Huang ZQ, Hawkins AE, Khazaeli MB, Kraus MH, Vickers SM. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 8: 960-9; discussion 96. PMID 15585383 DOI: 10.1016/J.Gassur.2004.09.021  0.423
2004 Kaliberov SA, Kaliberova LN, Stockard CR, Grizzle WE, Buchsbaum DJ. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1059-70. PMID 15564138 DOI: 10.1016/J.Ymthe.2004.08.024  0.454
2004 Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, Wang W, Bonner JA, Khazaeli MB, Buchsbaum DJ. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjugate Chemistry. 15: 1264-74. PMID 15546192 DOI: 10.1021/Bc049868V  0.383
2004 Buchsbaum DJ, Chaudhuri TR, Yamamoto M, Zinn KR. Gene expression imaging with radiolabeled peptides. Annals of Nuclear Medicine. 18: 275-83. PMID 15359919 DOI: 10.1007/Bf02984464  0.434
2004 Bonner JA, Buchsbaum DJ, Russo SM, Fiveash JB, Trummell HQ, Curiel DT, Raisch KP. Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. International Journal of Radiation Oncology, Biology, Physics. 59: 2-10. PMID 15142629 DOI: 10.1016/J.Ijrobp.2004.01.053  0.455
2004 Kaliberov S, Stackhouse MA, Kaliberova L, Zhou T, Buchsbaum DJ. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells Gene Therapy. 11: 658-667. PMID 14973547 DOI: 10.1038/Sj.Gt.3302215  0.473
2004 Bonner JA, Buchsbaum DJ, Rogers BE, Grizzle WE, Trummell HQ, Curiel DT, Fiveash JB, Ove R, Raisch KP. Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. International Journal of Radiation Oncology, Biology, Physics. 58: 950-8. PMID 14967455 DOI: 10.1016/J.Ijrobp.2003.09.095  0.51
2004 Buchsbaum DJ. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Seminars in Nuclear Medicine. 34: 32-46. PMID 14735457 DOI: 10.1053/J.Semnuclmed.2003.09.005  0.428
2004 Markert JM, Guffey MB, Manna DD, Buchsbaum DJ, Price KH, Langford CP, Gillespie GY. 1031. Improved Anti-Brain Tumor Efficacy of |[Delta]||[gamma]|134.5 HSV Expressing Cytosine Deaminase|[ast]| Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.976  0.572
2004 Kaliberov SA, Kaliberova LN, Buchsbaum DJ. 674. Improved Therapy of Prostate Carcinoma with TRAIL Gene Delivery Using Flt-1 Promoter Element in Combination with Ionizing Radiation Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.638  0.463
2003 Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3731-41. PMID 14506165  0.384
2003 Huang ZQ, Buchsbaum DJ, Raisch KP, Bonner JA, Bland KI, Vickers SM. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. The Journal of Surgical Research. 111: 274-83. PMID 12850474 DOI: 10.1016/S0022-4804(03)00076-3  0.449
2003 Roberson PL, Yokoyama S, Rogers BE, Buchsbaum DJ. Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts. Cancer Biotherapy & Radiopharmaceuticals. 18: 239-47. PMID 12804050 DOI: 10.1089/108497803765036418  0.351
2003 Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway Oncogene. 22: 2034-2044. PMID 12673208 DOI: 10.1038/Sj.Onc.1206290  0.419
2003 Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjugate Chemistry. 14: 302-10. PMID 12643740 DOI: 10.1021/Bc020033Z  0.601
2003 Arafat WO, Buchsbaum DJ, Gómez-Navarro J, Tawil SA, Olsen C, Xiang J, El-Akad H, Salama AM, Badib AO, Stackhouse MA, Curiel DT. An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. International Journal of Radiation Oncology, Biology, Physics. 55: 1037-50. PMID 12605984 DOI: 10.1016/S0360-3016(02)04488-7  0.523
2003 Arafat W, Buchsbaum D, Kaliberov S, Li F, Zhu Z, Curiel D. A novel radiation/tissue-specific promoter for gene therapy of brain tumors International Journal of Radiation Oncology*Biology*Physics. 57: S146. DOI: 10.1016/S0360-3016(03)00915-5  0.473
2002 Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Molecular Cancer Therapeutics. 1: 1139-45. PMID 12481438  0.524
2002 Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. International Journal of Radiation Oncology, Biology, Physics. 54: 1180-93. PMID 12419447 DOI: 10.1016/S0360-3016(02)03788-4  0.416
2002 Kaliberov SA, Buchsbaum DJ, Gillespie GY, Curiel DT, Arafat WO, Carpenter M, Stackhouse MA. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 190-8. PMID 12161185 DOI: 10.1006/Mthe.2002.0648  0.677
2002 Zinn KR, Chaudhuri TR, Krasnykh VN, Buchsbaum DJ, Belousova N, Grizzle WE, Curiel DT, Rogers BE. Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology. 223: 417-25. PMID 11997547 DOI: 10.1148/Radiol.2232010501  0.504
2002 Safavy A, Smith DC, Bazooband A, Buchsbaum DJ. De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent. Bioconjugate Chemistry. 13: 317-26. PMID 11906270 DOI: 10.1021/Bc0100861  0.308
2002 Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Therapy. 9: 256-62. PMID 11896464 DOI: 10.1038/Sj.Gt.3301639  0.546
2002 DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 94: 1332-48. PMID 11877764 DOI: 10.1002/Cncr.10304  0.33
2002 Rogers BE, Zinn KR, Lin CY, Chaudhuri TR, Buchsbaum DJ. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer. 94: 1298-305. PMID 11877760 DOI: 10.1002/Cncr.10300  0.446
2002 Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Research. 62: 773-80. PMID 11830532  0.605
2002 Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Analytical Biochemistry. 301: 189-99. PMID 11814289 DOI: 10.1006/Abio.2001.5511  0.411
2002 Buchsbaum DJ, Curiel DT. Gene therapy for the treatment of cancer. Cancer Biotherapy & Radiopharmaceuticals. 16: 275-88. PMID 11602998 DOI: 10.1089/108497801753131354  0.525
2001 Chaudhuri TR, Rogers BE, Buchsbaum DJ, Mountz JM, Zinn KR. A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecologic Oncology. 83: 432-8. PMID 11606113 DOI: 10.1006/Gyno.2001.6333  0.374
2001 Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR, Rogers BE, Buchsbaum DJ, Siegal GP, Barnes MN, Gomez-Navarro J, Curiel DT, Alvarez RD. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 223-31. PMID 11545613 DOI: 10.1006/Mthe.2001.0446  0.551
2001 Zinn KR, Chaudhuri TR, Buchsbaum DJ, Mountz JM, Rogers BE. Detection and measurement of in vitro gene transfer by gamma camera imaging. Gene Therapy. 8: 291-9. PMID 11313803 DOI: 10.1038/Sj.Gt.3301391  0.36
2001 Zinn KR, Chaudhuri TR, Buchsbaum DJ, Mountz JM, Rogers BE. Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. Nuclear Medicine and Biology. 28: 135-44. PMID 11295424 DOI: 10.1016/S0969-8051(00)00207-9  0.328
2000 Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM, Curiel DT. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 562-78. PMID 11124057 DOI: 10.1006/Mthe.2000.0205  0.468
2000 Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4323-33. PMID 11106250  0.535
2000 Arafat WO, Gómez-Navarro J, Xiang J, Barnes MN, Mahasreshti P, Alvarez RD, Siegal GP, Badib AO, Buchsbaum D, Curiel DT, Stackhouse MA. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 545-54. PMID 10933979 DOI: 10.1006/Mthe.2000.0071  0.604
2000 Vallera DA, Kuroki DW, Panoskaltsis-Mortari A, Buchsbaum DJ, Rogers BE, Blazar BR. Molecular modification of a recombinant anti-CD3ε-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model Blood. 96: 1157-1165. PMID 10910937 DOI: 10.1182/Blood.V96.3.1157  0.344
2000 Stackhouse MA, Pederson LC, Grizzle WE, Curiel DT, Gebert J, Haack K, Vickers SM, Mayo MS, Buchsbaum DJ. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models Gene Therapy. 7: 1019-1026. PMID 10871750  0.472
2000 Gustin AN, Kiss P, Elgavish GA, Lenard L, Buchsbaum DJ, Vickers SM. 19FNMR spectroscopic detection and kinetics of conversion of 5-FC to 5-FU in human colon cancer in vivo and in vitro: A novel approach for detecting adenoviral cytosine deaminase gene transfer Gastroenterology. 118. DOI: 10.1016/S0016-5085(00)86318-0  0.346
1999 Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biotherapy & Radiopharmaceuticals. 14: 451-63. PMID 10850332 DOI: 10.1089/Cbr.1999.14.451  0.438
1999 Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. Journal of Medicinal Chemistry. 42: 4919-24. PMID 10579854 DOI: 10.1021/Jm990355X  0.421
1999 Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SVS, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT. Targeting strategies for cancer radiotherapy Clinical Cancer Research. 5. PMID 10541342  0.497
1999 Stackhouse MA, Buchsbaum DJ, Kancharla SR, Grizzle WE, Grimes C, Laffoon K, Pederson LC, Curiel DT. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors Cancer Gene Therapy. 6: 209-219. PMID 10359206 DOI: 10.1038/Sj.Cgt.7700049  0.561
1999 Wheeler RH, Spencer S, Buchsbaum D, Robert F. Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer Current Opinion in Oncology. 11: 187-190. PMID 10328593 DOI: 10.1097/00001622-199905000-00009  0.434
1999 Rogers BE, McLean SF, Kirkman RL, Della Manna D, Bright SJ, Olsen CC, Myracle AD, Mayo MS, Curiel DT, Buchsbaum DJ. In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector Clinical Cancer Research. 5: 383-393. PMID 10037188  0.473
1999 Arafat W, Gomez-Navarro J, Xiang J, Barnes M, Alvarez R, Siegal G, Buchsbaum D, Stackhouse M, Curiel D. 70 Radiosensitization and chemosensitization of ovarian carcinoma by induction of apoptosis via recombinant adenovirus encoding bax International Journal of Radiation Oncology*Biology*Physics. 45: 182-183. DOI: 10.1016/S0360-3016(99)90088-3  0.461
1998 Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Research. 58: 5738-48. PMID 9865732  0.611
1998 Stackhouse MA, Buchsbaum DJ, Grizzle WE, Bright SJ, Olsen CC, Kancharla S, Mayo MS, Curiel DT. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. International Journal of Radiation Oncology, Biology, Physics. 42: 817-22. PMID 9845103 DOI: 10.1016/S0360-3016(98)00330-7  0.621
1998 Pederson LC, Vickers SM, Buchsbaum DJ, Kancharla SR, Mayo MS, Curiel DT, Stackhouse MA. Combined Cytosine Deaminase Expression, 5-Fluorocytosine Exposure, and Radiotherapy Increases Cytotoxicity to Cholangiocarcinoma Cells Journal of Gastrointestinal Surgery. 2: 283-291. PMID 9841986 DOI: 10.1016/S1091-255X(98)80024-3  0.509
1998 Pederson L, Buchsbaum D, Stackhouse M, Curiel D, Vickers S. Effective toxin gene expression via adenoviral infection of human cholangiocarcinoma cells in the presence of human bile Gastroenterology. 114: A1416. DOI: 10.1016/S0016-5085(98)85760-0  0.451
1997 Ram S, Merriwether W, Buchsbaum DJ. Synthesis and biodistribution of peptide based 99mTc/186Re- MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts Cancer Biotherapy and Radiopharmaceuticals. 12: 55-62. PMID 10851448 DOI: 10.1089/Cbr.1997.12.55  0.383
1997 Rosenfeld ME, Rogers BE, Khazaeli MB, Mikheeva G, Raben D, Mayo MS, Curiel DT, Buchsbaum DJ. Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo Clinical Cancer Research. 3: 1187-1194. PMID 9815798  0.505
1997 Rogers BE, Douglas JT, Ahlem C, Buchsbaum DJ, Frincke J, Curiel DT. Use of a novel cross-linking method to modify adenovirus tropism. Gene Therapy. 4: 1387-92. PMID 9472563 DOI: 10.1038/Sj.Gt.3300541  0.508
1997 Roberson PL, Dudek S, Buchsbaum DJ. Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model Cancer. 80: 2567-2575. PMID 9406711 DOI: 10.1002/(Sici)1097-0142(19971215)80:12+<2567::Aid-Cncr32>3.0.Co;2-8  0.337
1997 Rogers BE, Curiel DT, Mayo MS, Laffoon KK, Bright SJ, Buchsbaum DJ. Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to excess the gastrin-releasing peptide receptor by an adenoviral vector Cancer. 80: 2419-2424. PMID 9406692 DOI: 10.1002/(Sici)1097-0142(19971215)80:12+<2419::Aid-Cncr13>3.0.Co;2-F  0.524
1997 Buchsbaum DJ. Experimental tumor targeting with radiolabeled ligands Cancer. 80: 2371-2377. PMID 9406685 DOI: 10.1002/(Sici)1097-0142(19971215)80:12+<2371::Aid-Cncr6>3.0.Co;2-E  0.41
1997 Safavy A, Khazaeli MB, Qin H, Buchsbaum DJ. Synthesis of bombesin analogues for radiolabeling with rhenium-188 Cancer. 80: 2354-2359. PMID 9406683 DOI: 10.1002/(Sici)1097-0142(19971215)80:12+<2354::Aid-Cncr4>3.0.Co;2-B  0.355
1997 Pederson LC, Buchsbaum DJ, Vickers SM, Kancharla SR, Mayo MS, Curiel DT, Stackhouse MA. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo Cancer Research. 57: 4325-4332. PMID 9331094  0.485
1997 Rogers BE, Rosenfeld ME, Khazaeli MB, Mikheeva G, Stackhouse MA, Liu T, Curiel DT, Buchsbaum DJ. Localization of idine-125-mIP-Des-Met14bmbesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer Journal of Nuclear Medicine. 38: 1221-1229. PMID 9255155  0.474
1997 Safavy A, Khazaeli MB, Mayo MS, Buchsbaum DJ. Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin Cancer Biotherapy and Radiopharmaceuticals. 12: 375-384. DOI: 10.1089/Cbr.1997.12.375  0.322
1996 Buchsbaum DJ, Raben D, Stackhouse MA, Khazaeli MB, Rogers BE, Rosenfeld ME, Liu T, Curiel DT. Approaches to enhance cancer radiotherapy employing gene transfer methods Gene Therapy. 3: 1042-1068. PMID 8986431  0.483
1996 Raben D, Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Grizzle WE, Liu T, Curiel DT. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene Gene Therapy. 3: 567-580. PMID 8818643  0.65
1996 Buchsbaum DJ, Roberson PL. Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 141: 9-18. PMID 8722417 DOI: 10.1007/978-3-642-79952-5_2  0.318
1996 Muthuswamy MS, Roberson PL, Ten Haken RK, Buchsbaum DJ. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography International Journal of Radiation Oncology Biology Physics. 35: 165-172. PMID 8641915 DOI: 10.1016/S0360-3016(96)85026-7  0.359
1996 Raben D, Stackhouse M, Buchsbaum DJ, Mikheeva G, Khazaeli M, McLean S, Kirkman R, Krasnykh V, Curiel DT. 2207 Genetic induction of the gastrin releasing peptide receptor on tumor cells for radiolabeled peptide binding International Journal of Radiation Oncology*Biology*Physics. 36: 378. DOI: 10.1016/S0360-3016(97)85780-X  0.451
1996 Liu T, Buchsbaum DJ, Curiel DT, Khazaeli MB, Meredith RF, LoBuglio AF. Simulation of Tumor-Specific Delivery of Radioligand Comparison of One Step, Two Step, and Genetic Transduction Systems Journal of Molecular Modeling. 2: 467-477. DOI: 10.1007/S0089460020467  0.495
1995 Buchsbaum DJ. Experimental approaches to increase radiolabeled antibody localization in tumors Cancer Research. 55. PMID 7493336  0.306
1994 Buchsbaum DJ, Khazaeli MB, Davis MA, Lawrence TS. Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine Cancer. 73: 999-1005. PMID 8306292 DOI: 10.1002/1097-0142(19940201)73:3+<999::Aid-Cncr2820731338>3.0.Co;2-N  0.409
1994 Ram S, Buchsbaum DJ. Radioiodination of monoclonal antibodies D612 and 17-1A with 3- iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice Cancer. 73: 808-815. PMID 8306264 DOI: 10.1002/1097-0142(19940201)73:3+<808::Aid-Cncr2820731310>3.0.Co;2-R  0.379
1994 Ram S, Buchsbaum DJ. A peptide-based bifunctional chelating agent for 99mTc- and 186Re- labeling of monoclonal antibodies Cancer. 73: 769-773. PMID 8306258 DOI: 10.1002/1097-0142(19940201)73:3+<769::Aid-Cncr2820731304>3.0.Co;2-A  0.407
1993 Buchsbaum DJ, Wessels BW. Introduction: Radiolabeled antibody tumor dosimetry Medical Physics. 20: 499-501. PMID 8492757 DOI: 10.1118/1.597044  0.376
1993 Buchsbaum DJ, Lawrence TS, Roberson PL, Heidorn DB, Ten Haken RK, Steplewski Z. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts International Journal of Radiation Oncology, Biology, Physics. 25: 629-638. PMID 8454481 DOI: 10.1016/0360-3016(93)90009-K  0.363
1992 Roberson PL, Buchsbaum DJ, Heidorn DB, Ten Haken RK. Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography International Journal of Radiation Oncology, Biology, Physics. 24: 329-334. PMID 1526872 DOI: 10.1016/0360-3016(92)90689-F  0.326
1992 Buchsbaum DJ, Wahl RL, Normolie DP, Kaminski MS. Therapy with Unlabeled and 131I-labeled Pan-B-Cell Monoclonal Antibodies in Nude Mice Bearing Raji Burkitt's Lymphoma Xenografts Cancer Research. 52: 6476-6481. PMID 1423295  0.32
1991 Harney JV, Liebert M, Wedemeyer G, Washington R, Stein J, Buchsbaum D, Steplewski Z, Grossman HB. The expression of epidermal growth factor receptor on human bladder cancer: Potential use in radioimmunoscintigraphy Journal of Urology. 146: 227-231. PMID 2056595 DOI: 10.1016/S0022-5347(17)37757-1  0.467
1991 Schmidberger H, Buchsbaum DJ, Blazar BR, Everson P, Vallera DA. Radiotherapy in Mice with Yttrium-90-labeled Anti-Ly1 Monoclonal Antibody: Therapy of the T Cell Lymphoma EL4 Cancer Research. 51: 1883-1890. PMID 2004371  0.301
1991 Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Barton Grossman H, Fisher S. 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography Cancer. 67: 1544-1550. PMID 2001543 DOI: 10.1002/1097-0142(19910315)67:6<1544::Aid-Cncr2820670614>3.0.Co;2-0  0.419
1991 Srivastava PC, Buchsbaum DJ, Hasad A. Design, Synthesis and Tumor Specificity of Azomycin Ribo- and Acyclonucleosides Nucleosides, Nucleotides & Nucleic Acids. 10: 235-238. DOI: 10.1080/07328319108046450  0.328
1990 Buchsbaum DJ, Ten Haken RK, Heidorn DB, Lawrence TS, Glatfelter AA, Terry VH, Guilbault DM, Steplewski Z, LichterM AS. A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts International Journal of Radiation Oncology, Biology, Physics. 18: 1033-1041. PMID 2347713 DOI: 10.1016/0360-3016(90)90438-P  0.368
1990 Liebert M, Wedemeyer G, Chang JH, Stein JA, McKeever PE, Carey TE, Flint A, Steplewski Z, Buchsbaum DJ, Wahl RL. Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. The Journal of Urology. 144: 1288-92. PMID 2231915 DOI: 10.1016/S0022-5347(17)39721-5  0.339
1990 Buchsbaum DJ, Lawrence TS. New trends in the use of radioimmunoconjugates for the therapy of cancer Targeted Diagnosis and Therapy. 3: 215-255. PMID 2131011  0.321
1988 Manske JM, Buchsbaum DJ, Vallera DA. Cytotoxic effects of anti-cd5 radioimmunotoxins on human tumors in vitro and in a nude mouse model Cancer Research. 48: 7107-7114. PMID 2461252  0.345
1987 Buchsbaum DJ, Nelson LA, Hanna DE, Vallera DA. Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins International Journal of Radiation Oncology, Biology, Physics. 13: 1701-1712. PMID 3499427 DOI: 10.1016/0360-3016(87)90167-2  0.447
1986 Buchsbaum DJ, Hanna DE, Manske JM, Nelson LA, Vallera DA. Tumor cell binding and killing by CD5 radioimmunotoxins International Journal of Radiation Oncology Biology Physics. 12: 192-193. DOI: 10.1016/0360-3016(86)90698-X  0.342
1985 Buchsbaum D, Randall B, Hanna D, Chandler R, Loken M, Johnson E. Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium. European Journal of Nuclear Medicine. 10: 398-402. PMID 4006981 DOI: 10.1007/Bf00256578  0.329
1985 Buchsbaum DJ, Hanna DE, Randall BC, Buchegger F, Mach JP. Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88Y and biodistribution studies. International Journal of Nuclear Medicine and Biology. 12: 79-82. PMID 2412985 DOI: 10.1016/0047-0740(85)90160-3  0.372
1982 Buchsbaum DJ, Anderson JM, Bray BE. Localization of Radiolabeled Antibody in SVT2 Tumor Increases with Immunosuppression of the Host Proceedings of the Society For Experimental Biology and Medicine. 171: 56-64. PMID 6292920 DOI: 10.3181/00379727-171-41477  0.382
1974 Bale WF, Contreras MA, Izzo MJ, Della Penta D, Buchsbaum DJ. Preferential in vivo localization of 125I-labeled antibody in a carcinogen-induced syngeneic rat tumor Progress in Experimental Tumor Research. Fortschritte Der Experimentellen Tumorforschung. Progres De La Recherche Experimentale Des Tumeurs. 19: 270-283. PMID 4438642 DOI: 10.1159/000395861  0.651
1972 Buchsbaum DJ. Effect of Rat Tumor Allografts on the Blood Level of Passively Transferred Alloantibodies Proceedings of the Society For Experimental Biology and Medicine. 139: 1197-1201. PMID 4112429 DOI: 10.3181/00379727-139-36328  0.321
1972 Izzo MJ, Buchsbaum DJ, Bale WF. Localization of an 125I-Labeled Rat Transplantation Antibody in Tumors Carrying the Corresponding Antigen Proceedings of the Society For Experimental Biology and Medicine. 139: 1185-1188. PMID 4112428 DOI: 10.3181/00379727-139-36326  0.644
Show low-probability matches.